Afuco™ Anti-Human KLRC1 ADCC Therapeutic Antibody (IPH 2201), ADCC Enhanced
Anti-KLRC1 ADCC Enhanced Antibody (IPH 2201) is an ADCC enhanced antibody produced by our Afuco™ platform. IPH2201 is a first-in-class humanized IgG4 targeting NKG2A receptors expressed on tumor infiltrating cytotoxic NK and CD8 T lymphocytes. IPH2201 may re-establish a broad anti-tumor response mediated by NK and T cells. IPH2201 may also enhance the cytotoxic potential of other therapeutic antibodies. IPH2201 is currently in Phase II development in various cancer indications and combinations.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-453CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | KLRC1 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |